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Batista et al. demonstrate potent
transcriptional remodeling by
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Regulation of gene expression is an important aspect
of insulin action but in vivo is intertwined with chang-
ing levels of glucose and counter-regulatory hor-
mones. Here we demonstrate that under euglycemic
clamp conditions, physiological levels of insulin
regulate interrelated networks of more than 1,000
transcripts in muscle and liver. These include ex-
pected pathways related to glucose and lipid utiliza-
tion, mitochondrial function, and autophagy, as well
as unexpected pathways, such as chromatin remod-
eling, mRNA splicing, and Notch signaling. These
acutely regulated pathways extend beyond those
dysregulated in mice with chronic insulin deficiency
or insulin resistance and involve a broad network
of transcription factors. More than 150 non-coding
RNAs were regulated by insulin, many of which
also responded to fasting and refeeding. Pathway
analysis and RNAi knockdown revealed a role for
lncRNA Gm15441 in regulating fatty acid oxidation
in hepatocytes. Altogether, these changes in coding
and non-coding RNAs provide an integrated tran-
scriptional network underlying the complexity of in-
sulin action.
INTRODUCTION
Insulin is the primary hormone controlling the balance between
an anabolic and catabolic state. This occurs through regulation
of a range of physiological processes involved in metabolism,
growth, differentiation, and cell survival (Boucher et al., 2014; To-
karz et al., 2018). At the cellular level, insulin activates the insulin
receptor (IR) tyrosine kinase, which triggers two major down-
stream pathways: the IRS-1/phosphatidylinositol 3-kinase
(PI3K)/AKT pathway, which regulates most of insulin’s metabolic
actions, and the SHC/RAS/mitogen-activated protein kinase
(MAPK) pathway, which regulates growth and differentiation
(Haeusler et al., 2018; Taniguchi et al., 2006). In both its meta-
bolic and growth-promoting actions, insulin regulates the
expression of many genes, both through direct effects on gene
transcription and through indirect effects secondary to changing
levels of blood glucose and other hormones.
During fasting, for example, when insulin levels are low and
glucagon and glucocorticoid levels are high, the promoter of
the phosphoenolpyruvate carboxykinase 1 (Pck1) gene, a key
mediator of hepatic gluconeogenesis, is occupied by multiple
transcriptional activators, including FOXO1 and FOXO3,
FOXA2, SRC-1, CBP/p300, HNF4a, glucocorticoid receptor,
and the co-activator PGC1a (Granner, 2015). Feeding, which in-
creases insulin and decreases glucagon levels, induces rapid,
phosphorylation-dependent removal of most of these factors
fromPck1 promoter, leading to suppression of gluconeogenesis,
but to what extent this is the result of increased insulin action
versus decreased glucagon action is unclear.
Global mRNA profiling approaches have been useful in identi-
fying insulin-regulated genes in both cell lines and tissues taken
from animals before and after insulin administration, during fast-
ing and refeeding, or in the context of insulin resistance (Boucher
et al., 2010; Fazakerley et al., 2018; Yang et al., 2016). However,
these studies have limitations in the interpretation, because all of
these manipulations result in changes of glucose levels, as well
as levels of other hormones and metabolites. The gold standard
method for assessing insulin action isolated from these other ef-
fects is the hyperinsulinemic-euglycemic clamp (Kim, 2009). In
this regard, some microarray-based profiling of mRNAs has
been performed in skeletal muscle biopsies from healthy and
insulin-resistant human subjects undergoing hyperinsulinemic-
euglycemic clamps (Coletta et al., 2008; Rome et al., 2003; Sears
et al., 2009); however, little has been done using more compre-
hensive approaches like RNA sequencing (RNA-seq), which
allows measurement of all transcripts, including multiple iso-
forms due to alternative splicing and the expression of non-cod-
ing RNA (ncRNA) species. Likewise, in the human studies, there
was no assessment of insulin regulation of gene expression in
the liver due to sampling limitations.
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Figure 1. Euglycemic Clamp, Insulin Signaling, and Gene Expression in Muscle and Liver
(A) Plasma insulin levels before and after hyperinsulinemic-euglycemic clamp with 4 or 12 mU/kg/min insulin infusion for 20 min or 3 h (n = 2–4). Data are mean ±
SEM (n = 6), *p < 0.05, ***p < 0.01, ****p < 0.0001, two-way ANOVA.
(B) Glucose infusion rates indicated as average of t = 10–15min for the 20min clamp and t = 120–150min for the 3 h clamp. ***p < 0.001, Student’s t test. Data are
mean ± SEM.
(legend continued on next page)
3430 Cell Reports 26, 3429–3443, March 19, 2019
To address gene expression changes induced by insulin under
constant blood glucose levels, where the effects of counter-reg-
ulatory hormones are minimized, we have performed transcrip-
tomic analysis in muscle and liver isolated frommice during a eu-
glycemic clamp.We find that insulin regulates >1,000 transcripts
in muscle and liver. These changes involve many well-known
pathways related to energymetabolism, development, and auto-
phagy, as well as previously unrecognized pathways, including
chromatin remodeling and multiple ncRNAs, many of these
with unknown function. Knockdown of selected long ncRNAs
(lncRNAs) identified by lncRNA-mRNA correlation analysis in he-
patocytes reveals a role for Gm15441 in regulation of fatty acid
oxidation (FAO) and lipid accumulation. Thus, the response to
physiological insulin levels in vivo is associated with a multi-level
network of tissue-specific regulation of coding and ncRNAs pro-
ducing the broad, pleiotropic actions of the hormone.
RESULTS
In Vivo Insulin Action and Gene Expression in Skeletal
Muscle and Liver
To assess the regulation of gene expression in skeletal muscle
and liver in response to physiological insulin levels, without inter-
ference of changing glucose levels or counter-regulatory hor-
mones, we performed hyperinsulinemic-euglycemic clamps on
conscious mice at low and high physiological (4 or 12 mU/
kg/min) insulin infusion rates and collected samples at 20 min
and 3 h (Kim, 2009). These doses are within ranges that effec-
tively suppress endogenous glucose production (Ayala et al.,
2006; Berglund et al., 2008) while producing half-maximal to
maximal effects on glucose uptake (Shen et al., 1999). After
some transient, mild increases in glucose in control mice at early
time points, blood glucose of all mice remained between 110 and
150 mg/dL throughout the experiment (Figure S1A). At both
time points, low and high insulin infusions raised plasma insulin
levels to 1.7 ± 0.1 or 5.9 ± 0.5 ng/mL, representing levels seen
during refeeding of fasted mice (O’Neill et al., 2015) or after an
intraperitoneal glucose tolerance test (ipGTT) (Andrikopoulos
et al., 2008), respectively (Figure 1A). In the 20 min clamp and
at early time points in the 3 h clamp, the glucose infusion rate
(GIR) increased in a dose-dependent manner, but by 3 h, GIR
had plateaued and was similar between insulin doses (Figures
1B and S1B).
Insulin signaling dynamics during the clamp are shown in Fig-
ures 1C, 1D, S1C, and S1E. Infusion with high doses of insulin led
to IR and/or IGF1 receptor (IGF1R) tyrosine phosphorylation in
both muscle and liver by 20 min, which was further increased
at 3 h. Total IR protein levels were significantly downregulated
at 3 h inmuscle but remained stable in liver, indicating differential
effects of insulin to downregulate the IR in these two tissues. By
contrast, IGF1R remained unaltered in muscle but increased
with time in liver. Downstream, tyrosine phosphorylation of
IRS-1 in muscle peaked at 20 min and then gradually declined,
while in liver, IRS-1 phosphorylation continued to increase to
the 3 h point. In both tissues, p-AKT levels were maximal by
20 min, while phosphorylation of its downstream target FOXO1
increased more slowly. Phosphorylation of ERK1/2 was more
variable between animals but transiently increased at 20 min
and returned to near-basal levels at 3 h.
Despite the rapid signaling events, transcriptomic profiling by
RNA-seq 20 min into the clamp revealed no significantly regu-
lated genes in muscle and only one significantly regulated
gene in liver, heat shock protein family A member 1B (Hspa1b),
which was downregulated by both low and high insulin. By 3 h,
however, insulin stimulation produced robust and dose-depen-
dent gene regulation in both tissues. In skeletal muscle, of
13,142 genes detected, using a false discovery rate (FDR) cutoff
of 0.1, there were 141 and 1,497 regulated genes with low and
high insulin, respectively (Figure 1E, left). In liver, of 13,482 genes
detected, we found 388 and 1,013 genes regulated by low and
high insulin (Figure 1E, right). For both tissues, significantly
changed genes were similarly distributed between upregulated
and downregulated. About 9% of the significantly regulated
genes in muscle and liver were non-protein coding (Figure 1E).
Not surprisingly, the effects of insulin were highly tissue specific,
with only about 10% of genes commonly regulated in both
tissues (Figure 1F). This interesting subset included genes
related to lipid and sterol metabolism and transcriptional regula-
tion (Table S1).
Insulin-Regulated Transcriptional Networks in Skeletal
Muscle and Liver
Genes regulated by high-dose insulin in skeletal muscle are
shown in a volcano plot in Figure 2A and in heatmap form in
Figure 2B. Among the most downregulated genes were two
catabolic genes involved in protein ubiquitination (Fbxo32) and
autophagy (Depp) and twomembers of the alpha-arrestin family,
thioredoxin-interacting protein (Txnip) and arrestin domain-
containing 3 (Arrdc3). Among the most upregulated genes
were mediators of myofiber contraction, myosin light chain 2
(Myl2) and myomesin 3 (Myom3), FAO, acyl coenzyme A (CoA)
synthetase 3 (Acsm3), and 3-hydroxybutyrate dehydrogenase 1
(Bdh1). Changes in expression of these top-ranking genes were
confirmed by qPCR (Figure S2A).
To better visualize the effects of insulin on skeletal muscle at a
system level, we constructed protein-protein interaction net-
works (Szklarczyk et al., 2017) from gene expression data (Fig-
ure 2C; Table S2). This approach identified 11 sets of genes
that were highly coordinated in their response to insulin stimula-
tion, with some including as many as 22 genes in a single
pathway. Insulin positively regulated multiple members of gene
sets involved in the tricarboxylic acid (TCA) cycle, electron trans-
port chain, muscle function, and glucose and lipid metabolism.
In addition to these nuclear-encoded genes, insulin increased
(C andD) Insulin signaling in (C)muscle and (D) liver frommice infusedwith high insulin for 20min or 3 h (n = 6). For basal levels, 3 samples from saline-infusedmice
at each time point were used. See also Figure S1.
(E) Number of regulated genes by low- and high-dose insulin at 3 h (FDR < 0.1).
(F) Venn diagrams of tissue-specific and overlapping genes regulated by low and high insulin.
See also Table S1.
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mRNA levels of 19 genes encoded by mtDNA by R1.5-fold,
including components of the electron transport chain (mt-Nd1
and mt-Co1) (Figure 2C) and tRNAs (mt-Tl1 and mt-Tp)
(Table S3), consistent with a coordinated increase in mitochon-
drial biogenesis. Conversely, insulin downregulated gene clus-
ters involved in insulin action, components of mTOR signaling
and autophagy pathways, and protein ubiquitination. Pathway
analysis confirmed enrichment for several of these gene clusters
(Figures S3A and S3B). In addition to these classical pathways,
insulin downregulated unanticipated gene sets associated with
chromatin remodeling and mRNA splicing. The former allows
refinement of the transcriptional program by altering chromatin
structure, which determines accessibility of transcription factors
to gene promoters (Hota and Bruneau, 2016), while the latter
allows alternative assembly of the transcribed mRNAs (Chen
and Manley, 2009).
In general, the total number of mRNAs regulated in the liver
was less than that in muscle, but the magnitude of regulation
was greater, with some mRNAs showing up to 37-fold changes
during the clamp. In liver, the top-ranking downregulated genes
included the catalytic subunit of glucose-6-phosphatase (G6pc),
a rate-limiting enzyme controlling glucose production, and
plasmamembrane transporters for omega-3 fatty acids (Mfsd2a)
and mitochondrial carriers for glutamate (Slc25a22) and ATP/
Mg-Pi (Slc25a25) (Figure 3A). Simultaneously, genes involved
in glucose utilization (Gck) and lipid storage (Angptl8) were
among the most upregulated (Figure 3B). Many of these were
confirmed by qPCR (Figure S2B). Analysis of transcriptional net-
works controlled by insulin in the liver (Figure 3C; Table S2)
showed fewer and smaller clusters. Insulin increased expression
of mediators of Toll-like receptor and Notch signaling pathways,
steroid and cholesterol biosynthetic enzymes, and several
members of the hepatocyte nuclear factor family of transcription
factors, some of which are defective in maturity onset diabetes
of the young (MODY). Gene clusters involved in FAO, gluconeo-
genesis, and transcription were predominantly downregulated.
These clusters were confirmed by pathway analysis (Figures
S3C and S3D).
Identification of Candidate Upstream Regulators by
Motif Enrichment Analysis
To identify the potential mediators of these changes in gene
expression, we analyzed sequences 2 kb upstream or down-
stream of the transcription start site (TSS) in all regulated genes
for transcription factor binding motifs. In muscle, promoter re-
gions of upregulated genes were highly enriched for sites for
C/EBPb, EVI1 (also known as PRDM3), transcription factors
involved in muscle development (Myogenin/NF-I and MEF2A),
factors previously identified as being involved in insulin action
(ETS2), and nuclear receptors, including steroidogenic factor 1
(SF1), estrogen receptor (ER), and estrogen-related receptor
alpha (ERRa) (Figure 4A). Of 155 genes upregulated by insulin
that showed enrichment for ERRa binding motifs, 51 overlapped
with ERRa targets previously identified by chromatin immuno-
precipitation sequencing (ChIP-seq) in PGC1a-overexpressing
C2C12 myotubes (Salatino et al., 2016) (Figure S4), including
genes involved in the TCA cycle (Mdh1 and Idh3a) and oxidative
metabolism (Cyc1 and Atp5c1) (Figure 4B, top).
Among downregulated genes, the most enriched transcription
factor motifs were several previously shown to be involved in
control of metabolism and insulin action (USF and SREBP1)
(Mounier and Posner, 2006), mTOR signaling (YY1) (Cunningham
et al., 2007), and signaling by vitamin D receptor (VDR) (Wang
et al., 2012) (Figure 4A). Consistent with the model of nuclear
exclusion of FoxO proteins following insulin-induced phosphor-
ylation by AKT (Nakae et al., 2000; O’Neill et al., 2016), a large
fraction of the downregulated genes had binding sites for
FOXO1, FOXO3, and FOXO4 (Figure 4B, bottom).
In the liver, most insulin-upregulated genes contained tran-
scription factor binding sites for factors related to developmental
pathways involving hepatocyte nuclear factor (HNF) 1 and HNF4
(Sheaffer and Kaestner, 2012), homeodomain proteins (NCX,
MEIS1/HOXA9, and CDP) (Azcoitia et al., 2005; Borghini et al.,
2006; Xu et al., 2010), and the bile acid receptor FXR, as well
as for factors related to cell-cycle regulation (NF-Y and E2F) (Di
Agostino et al., 2006; Tu et al., 2006) (Figure 4C). Of the 29 upre-
gulated genes that showed HNF1 binding sites, 23 have been
identified by ChIP-seq analysis as HNF1a targets in HepG2 he-
patocytes (Davis et al., 2018) (Figure 4D, top, and Figure S4).
However, genes containing promoter motifs related to lipid
metabolism (PPARa, PPARg, and SREBP1) and cyclic AMP
(cAMP) action (B-ATF, ATF1/3, CREB, and CREBP1) were en-
riched in downregulated genes (Figure 4C). Consistent with the
pivotal role of insulin in the transition to the post-absorptive state
through suppression of cAMP signaling, several fasting-related
genes possessing binding sites for activating transcription factor
(ATF) proteins were found to be downregulated (Figure 4D,
bottom).
SREBP1 is translated into a 125 kDa precursor protein that,
following sterol depletion or insulin action, gets cleaved into an
active 68 kDa isoform that translocates to the nucleus and
stimulates transcription of several genes involved in lipogenesis
(Horton et al., 2002). In the 3 h clamp, SREBP1 activation was
confirmed by a 2-fold increase of the cleaved isoform in both
muscle and liver (Figures S4C and S4D). Fatty acid synthase
(FAS), a well-known target of SREBP1, followed the same
increasing trend. In both muscle and liver, we also observed
enrichment of SREBP1 motifs, especially in downregulated
genes, including those related to transcription, notch, and
wnt signaling (Figure S4E), suggesting additional functions of
SREBP1 that go beyond regulation of lipogenesis. Thus, multiple
general and tissue-specific transcription factors underlie the
Figure 2. Insulin Regulation of Gene Expression in Skeletal Muscle
(A) Volcano plot showing distribution of differentially expressed genes (in red) by high insulin at 3 h compared to basal on the log2 scale.
(B) Heatmap showing the top 50 insulin-regulated genes. See also Figure S2.
(C) Network of predicted protein-protein interactions fromSTRING analysis (Szklarczyk et al., 2017) using insulin-regulated genes inmuscle as input. 1,406 nodes
and 6,369 interactions were detected (p < 1 3 1016). Colors of nodes represent log2 fold change values of insulin regulation.
See also Figure S3 and Tables S2 and S3.
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diverse effects of insulin on gene expression in skeletal muscle
and liver.
Identification of Insulin-Regulated Pathways in Diabetic
States
Diabetes is a state of impaired insulin signaling due to either lack
of insulin (type 1 diabetes) or insulin resistance (type 2 diabetes).
Both of these can lead to altered gene expression due to the
loss of insulin signaling, as well as to secondary factors such
as hyperglycemia, changes in other hormones, inflammation,
and generation of reactive oxygen species (Lan et al., 2003; Ye-
choor et al., 2004; Yip and Fathman, 2014). To identify pathways
directly regulated by insulin action within those dysregulated in































































































































































































































































































































































































































































































































































































































Figure 3. Insulin Regulation of Gene Expres-
sion in Liver
(A) Volcano plot showing distribution of differen-
tially expressed genes (in red) in liver by high insulin
at 3 h compared to basal on the log2 scale.
(B) Heatmap showing the top 50 insulin-regulated
genes. See also Figure S2.
(C) Network of predicted protein-protein in-
teractions from STRING analysis (Szklarczyk et al.,
2017) using insulin-regulated genes in liver as input.
933 nodes and 2,895 interactions were detected
(p < 13 1016). Colors of nodes represent log2 fold
change values of insulin regulation.
See also Figure S3 and Table S2.
in muscle and livers from insulin-defi-
cient streptozotocin (STZ)-treated mice
(Franko et al., 2014; Kivela¨ et al., 2006)
and insulin resistance due to high-fat
diet (HFD) feeding (Almind and Kahn,
2004), looking for inversely correlated
genes (Figure 5A). Of the 741 mRNAs
measured in all studies whose expression
was regulated by insulin during the clamp
in muscle, 58 were inversely regulated in
STZ diabetes and 196 were inversely
regulated in HFD-induced insulin resis-
tance. Of these reciprocally regulated
genes, 22 were common to both patho-
physiological conditions (Table S4).
These related to mitochondrial function,
electron transport chain, and TCA cycle
activity (Figure 5B). Of the 483 mRNAs
regulated by insulin in liver measured in
all studies, 86 were inversely regulated
in STZ, 82 were inversely regulated
in HFD-induced diabetes, and 20 were
common between these diabetic condi-
tions (Figure 5C; Table S4). These were
mainly associated with transcriptional
regulation and transport of organic anions
(Slc22a23 and slc22a30) and cationic
amino acids (slc7a2). In both tissues,
almost 70% of the genes regulated by
insulin during the clamp were not significantly altered by either
disease state, suggesting that in these chronic conditions, there
are compensatory mechanisms that protect against some of
the dysregulated gene expression that would result from a loss
of insulin action.
Insulin Regulation of ncRNA Species
In addition to coding genes, more than 150 ncRNAs were dose-
dependently regulated by insulin in muscle and liver (Figure 1E).
This is likely an underestimate of the true effect, because library
preparation for this study was not designed to capture miRNAs
and other very small and non-polyadenylated RNAs. As with
coding genes, insulin regulation of ncRNAs at 3 h in response
to the higher insulin dosewas tissue specific, with only 4 ncRNAs
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being commonly regulated in muscle and liver, and all of these
were downregulated (Figure 6A). More than 60% of the remain-
ing 163 uniquely regulated ncRNAs were lncRNAs, including
long intergenic ncRNAs (lincRNAs), antisense RNAs, and pseu-
dogene RNAs (Figure 6B). Top lncRNAs regulated by a high insu-
lin dose in muscle and liver are shown in Figures 6C and 6D, and
these were confirmed by qPCR (Figure S5).
Binding motif analysis revealed various transcription factors in
mediating the effects of insulin on regulation of ncRNAs. In mus-
A B
DC
Figure 4. Transcription Factor Motifs En-
riched in Insulin-Regulated Genes in Muscle
and Liver
(A and C) Overrepresented transcription factor
motifs within 2 kb of TSS in (A) muscle and (C) liver.
Plots are percentages of predicted target genes
that are significantly up- or downregulated by
insulin (FDR < 0.1). Enrichment analysis was
performed using data from low and high insulin
samples combined (n = 12).
(B) Examples of genes in muscle showing enrich-
ment for ERRa (top) and FOXO1 (bottom) binding
motifs.
(D) Examples of genes in liver showing enrichment
for HNF1 (top) and ATF protein (BATF, ATF3, and
CREB) (bottom) binding motifs.
See also Figure S4.
cle, many upregulated ncRNAs showed
enrichment of binding sites for tran-
scription factors involved in develop-
ment such as AT-rich interaction domain
(ARID3A) and homeobox (HOXC8,
HOXD3, and HOXA3) proteins (Figure 6E).
We also detected binding sites for tran-
scriptional regulators found enriched
among coding genes (MYOD1, ERRa,
FOXO3, and SREBP1); however, in the
case of ncRNAs, the direction of regulation
was similar between upregulated and
downregulated transcripts. Binding sites
for developmental transcription factors
(DMBX1 and NR2F2) and transcription
factors related to stress response
and metabolic adaptation (FOXK1, XBP1,
CREB1, FOXO3, and ATF3) were also
present among insulin-regulated ncRNAs
in liver (Figure 6F).
To determine whether the lncRNAs
regulated during the clamp are responsive
to physiological fluctuations of insulin
levels, we subjected mice to a fasting
and refeeding paradigm in which samples
were collected from three groups of mice:
ad libitum fed, overnight fasted, and over-
night fasted followed by 8 h of refeeding.
As expected, the expression of G6pc and
Gck, which are known to respond to
feeding cycles (Haeusler et al., 2014) and
are major transcriptional targets of insulin in the liver, showed
the expected changes, with G6pc expression significantly
increased by overnight fasting and returning to ad libitum levels
upon refeeding, while Gck was reciprocally regulated with
decreased levels after fasting, which returned above ad libitum
levels upon refeeding (Figures 7A and 7B, insets). Likewise,
many lncRNAs downregulated during the clamp were upregu-
lated by fasting, generally by 2- to 4-fold, although some
changed by more than 100-fold, such as Gm15441. Upon
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refeeding, most of these returned to ad libitum levels or lower,
consistent with the pattern of regulation seen during the clamp
(Figure 7A). In the case of lncRNAs upregulated by insulin,
although there was less robust regulation by fasting and
refeeding, lncRNA Gm11967 was significantly downregulated
by fasting and increased upon refeeding, and others such as
C730036E19Rik, Gm15622, and Gm16559 showed a similar
trend (Figure 7B). Thus, the transcriptional remodeling promoted
by insulin during the clamp is associated with regulation of mul-
tiple lncRNAs. These lncRNAs are also sensitive to fasting and
refeeding, indicating a role in metabolic adaptation to nutritional
status.
Identification of Gm15441 as a Regulator of Lipid
Metabolism
The regulatory roles exerted by lncRNAs extend to virtually every
step of the transmission of genetic information, including tran-
scription, mRNA processing, translation, and degradation (Ville-




Figure 5. Genes Inversely Regulated during
the Euglycemic Insulin Clamp, STZ Diabetes,
and HFD Obesity in Muscle and Liver
(A) Schematics of insulin clamp and STZ or HFD
dataset comparisons.
(B and C) Overlap of inversely correlated genes
among insulin, STZ diabetes, and HFD obesity in
muscle (B) and liver (C). Genes representing the
overlap of all conditions grouped by functional
annotation and cellular localization are indicated.
Edges represent predicted protein-protein in-
teractions from STRING. Colors of nodes are log2
fold change values of regulation by insulin.
See also Table S4.
annotated on pathway databases, we
performed correlation analysis of lncRNA-
mRNA expression changes in muscle and
liver (Table S5) and, from these sets of cod-
ing genes, analyzed the associated biolog-
ical processes. This approach has been
previously employed to identify metabolic
roles of lncRNAs in liver (Li et al., 2015;
Yang et al., 2016).
Based on gene expression changes
in liver seen in the clamp and fasting
and refeeding experiments, we selected
the downregulated lncRNAs Gm15663
and Gm15441 and upregulated lncRNA
Gm11967 for follow-up studies. These
were also of interest, because Gm11967
and Gm15441 are close to two other insu-
lin-regulated genes, Gck and Txnip genes
(Figure S6A), which are well-established
regulators of glucose homeostasis in
mice and humans (Chutkow et al., 2010;
Parikh et al., 2007; Postic et al., 1999;
Steele et al., 2014). Gene ontology (GO)
analysis of the correlatedmRNAs indicated
an association of Gm11967 expression with pathways related
to differentiation and development, while Gm15663 showed
enrichment with mineral transport (iron, copper, and sulfur), the
mitochondrial genome, and stem cell maintenance, as well as
fatty acid transport and oxidation (Figure S6B; Table S6). For
Gm15441, however, eight of the top ten correlated pathways
were related to lipid metabolism.
Using RNAi, we knocked down Gm11967, Gm15663, and
Gm15441 in mouse primary hepatocytes with an efficiency of
55% to 89%. This occurred without changes in expression
of neighboring genes (Figure S6C), confirming the specificity of
the knockdown and suggesting that these lncRNAs are more
likely to function in trans on more distant genomic regions.
Consistent with our initial prediction, knockdown of both
Gm15663 and Gm15441 resulted in downregulation of genes
involved in lipid transport (Cd36) and b-oxidation (Cpt1a and
Hadha), while knockdown of Gm11967 had no effects on genes
involved in lipid metabolism (Figure 7C). Changes in CPT1A and
HADHA following Gm15441 knockdown were confirmed at the





(legend on next page)
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protein level (Figure 7D). These effects were specific to fatty acid
metabolism, because genes involved in gluconeogenesis and
cholesterol and steroid synthesis remained largely unaffected
by knockdown of either of these lncRNAs (Figure S7A). Knock-
down of Gm15663 and Gm15441 also downregulated the
major transcriptional regulator of lipid metabolism Ppar gamma
by 50%–60%, while Ppar alpha expression was reduced by
Gm11967 knockdown and Ppargc1a (PGC1a), which co-acti-
vates both of these nuclear receptors, was specifically downre-
gulated by Gm15441 knockdown (Figure S7B).
Altogether, the pathway analysis and gene expression studies
indicated that Gm15441 was the lncRNA most closely related to
metabolic adaptation and specifically to lipid metabolism. To
further explore this link at a functional level, we knocked down
Gm15441 in the mouse hepatocyte cell line AML-12. This
occurred with an efficiency of 70% (Figure S7C), similar to that
in primary hepatocytes, and was accompanied by downregula-
tion ofCpt1a plus a reduction of other b-oxidation genes (Acadm
and Acadl) (Figure S7D) and the transcriptional regulators of lipid
metabolism, Ppar gamma and Ppargc1a (Figure S7E). In a lipid
accumulation assay using palmitic acid as substrate, control
cells showed a 3-fold increase in intracellular triglyceride levels,
and this was enhanced byGm15441 knockdown (Figure 7E). The
latter was associated with a 25% reduction in FAO rates and a
nearly significant decrease of b-hydroxybutyrate, a ketone by-
product of fatty acid catabolism, in culture supernatants (Fig-
ure 7F). These changes were not attributable to differences in
fatty acid uptake (Figure 7G). Collectively, these data indicate
that Gm15441 is an insulin-sensitive lncRNA that contributes to
regulation of the FAO program.
DISCUSSION
Loss of transcriptional integrity in response to insulin deficiency
is linked to many features of uncontrolled diabetes (Patti, 2004;
Sears et al., 2009). While much is known from in vitro studies
about insulin regulation of gene expression, establishing a
comprehensive view of insulin-regulated transcriptional net-
works in vivo in a tissue-specific manner is more difficult,
because glucose homeostasis involves a complex metabolic
response of insulin, multiple counter-regulatory hormones, and
othermetabolites. In the present study, we have assessed the ef-
fects of insulin on gene expression at constant blood glucose
levels by performing euglycemic clamps at low and high physio-
logical levels of insulin comparable to those observed after
feeding or during an oral glucose challenge. We find that in
both muscle and liver, insulin acutely regulates a broad and
multi-dimensional network of gene expression.
Although the euglycemic clamp is the best availablemethod to
assess insulin action at constant blood glucose levels and with
minimal counter-regulation (Kim, 2009), there are methodolog-
ical considerations. First, constant insulin infusion does not reca-
pitulate the dynamic nature of insulin secretion, which may be
more efficient in regulation of insulin action (Matveyenko et al.,
2012). Second, by its nature, a clamp is based on peripheral in-
sulin delivery, whereas physiologically insulin is secreted into the
portal vein, thus changing the balance of effects in muscle
compared to liver (Farmer et al., 2015). Third, repeated tail tip
blood sampling may have an impact on catecholamine levels,
although this would also affect the control mice receiving saline
(Ayala et al., 2006).
In muscle, mitochondria are a major target of insulin’s tran-
scriptional actions, with coordinate regulation of both nuclear
and mtDNA transcripts linked to glucose utilization through the
TCA cycle and oxidative phosphorylation, as well as recruitment
of genes involved in glycogenesis and triglyceride synthesis for
glucose storage. This transcriptional response is consistent
with the role of insulin in muscle as the major site of glucose
disposal during the clamp (Thiebaud et al., 1982). The nuclear re-
ceptor ERRa is a likely a major upstream regulator of the tran-
scriptional response to insulin associated with mitochondrial
metabolism, as indicated by enrichment of ERRa binding sites
within promoters of many insulin-regulated genes involved with
oxidative metabolism and by increased mRNA levels of the tran-
scriptional co-activator Ppargc1b (PGC1b), which is essential for
ERRa activity (Mootha et al., 2004), as well as increased levels of
the ERRa downstream target Perm1 (Cho et al., 2013) in the in-
sulin-stimulated state. In addition to control of glucose utiliza-
tion, a major function of insulin in muscle is prevention of protein
breakdown (Abdulla et al., 2016). Consistent with this anticata-
bolic function, during the clamp there is suppression of auto-
phagy genes and E3-ubiquitin ligases. These major pathways
regulating muscle proteostasis have been shown to be
controlled by FoxO transcription factors (O’Neill et al., 2019;
Sandri et al., 2004). Several insulin-regulated autophagy genes
(including Ulk1 and Tbc1d17) showed enrichment for FOXO1,
FOXO3, and FOXO4 binding sites on promoter regions, consis-
tent with highest FOXO1/3 phosphorylation at 3 h.
Impaired expression of genes involved in oxidative meta-
bolism is observed in muscle from subjects with type 1 diabetes
(Karakelides et al., 2007) and type 2 diabetes (T2D) (Mootha
et al., 2003; Patti et al., 2003). Intersection of genes regulated
by insulin in muscle during the clamp with data from STZ and
HFD models reveals that downregulation of mitochondrial func-
tion genes related to TCA cycle and oxidative phosphorylation in
diabetes is linked to impaired insulin action. The relationship
between insulin resistance and diabetic state on gene expres-
sion is illustrated by comparing mice with IR knockout in muscle
(MIRKO) and mice made diabetic by STZ treatment (Yechoor
et al., 2004). In this comparison, genes of oxidative phosphor-
ylation are downregulated by STZ diabetes but remain un-
changed upon muscle-specific deletion of the IR, indicating
Figure 6. Regulation of Non-coding RNA Species by Insulin
(A) Venn diagrams of tissue-specific and overlapping ncRNAs regulated by high insulin at 3 h.
(B) Number of insulin-regulated lncRNAs across three main categories: lincRNA, antisense RNAs, and pseudogenes in muscle and liver.
(C and D) Heatmaps of top lncRNAs regulated in muscle (C) and liver (D) by high insulin at 3 h. See also Figure S5.
(E and F) Overrepresented transcription factor motifs within 2 kb upstream and 0.2 kb downstream of TSS and example ncRNAs for selected factors in (E) muscle
and (F) liver. Plots are percentages of predicted target genes that are significantly up- or downregulated by a high insulin dose (FDR < 0.1).




Figure 7. Physiological Regulation and Effect of lncRNA Gm15441 Knockdown on Fatty Acid Oxidation
(A and B) Expression of (A) downregulated and (B) upregulated lncRNAs by insulin in the clamp in livers of 14- to 16-week-old ad libitum fed, overnight fasted, and
8 h refed mice. Gene expression was normalized to TBP. Data are means ± SEM, n = 4–5, *p < 0.05, **p < 0.01, ****p < 0.0001, one-way ANOVA.
(legend continued on next page)
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that metabolic factors other than insulin resistance are involved
in the downregulation of mitochondrial genes. Insulin replace-
ment restores gene expression in lox-STZ mice, but not in
MIRKO-STZ mice, indicating that insulin action provides an initi-
ating force in this gene regulation.
In the liver, insulin upregulates genes involved in steroid and
cholesterol biosynthesis and downregulates pathways related
to glucose production and fatty acid catabolism. In terms of sup-
pression of endogenous production in liver, insulin action to
phosphorylate FOXO1 plays a central role in increasingGck tran-
scription while suppressing G6pc levels (Haeusler et al., 2014).
Insulin resistance in liver due to deletion of the IR or its down-
stream partners, IRS proteins or AKT1/AKT2, is characterized
by unrestrained gluconeogenesis, and this can be reversed by
liver-specific deletion of FOXO1 (Lu et al., 2012; Matsumoto
et al., 2007; O-Sullivan et al., 2015). In our study, the involvement
of FOXOs in the transcriptional response to insulin in the liver is
indicated by increase of FOXO1 and FOXO3 phosphorylation
in association with coordinate upregulation of Gck and downre-
gulation of G6pc and other canonical FOXO targets in the liver,
such as Pck1, Igfbp1, and Ppargc1a.
HNFs also appear to mediate part of the transcriptional effects
of insulin in liver metabolism. During the 3 h clamp, insulin in-
creases the expression of Foxa2 (HNF3b), Foxa3 (HNF3g), One-
cut1 (HNF6a), and Onecut2 (HNF6b) in the liver, and promoters
of several regulated genes are enriched for HNF1 and HNF4
binding motifs. Insulin has been shown to also regulate liver tran-
scription factors at the post-translational level, such as by pro-
moting the inhibitory phosphorylation of FOXA2 at Thr156 by
AKT, resulting in nuclear exclusion and suppression of gluconeo-
genesis genes (Wolfrum et al., 2003), and through FOXO1 phos-
phorylation, which disrupts an inhibitory interaction with HNF4a,
thus promoting its transcriptional activity (Hirota et al., 2008).
Thus, HNFs, in combination with FOXOs, play important roles
in determining the transcriptional response to insulin in the liver.
Control of lipid metabolism is a central metabolic function of
insulin and occurs with different transcriptional profiles in muscle
and liver. In liver, 3 h insulin stimulation downregulates the rate-
limiting FAO enzymes Cpt1a and Cpt2 and increases genes
involved in steroid and cholesterol biosynthesis (Hmgcs1 and
Sqle), whilemRNA levels of themajor lipogenic genes remain un-
changed at this time point. In muscle, insulin increases expres-
sion of enzymes of triglyceride synthesis (Gk and Dgat2), as
well as genes involved in de novo lipogenesis (Fasn and Acly).
Most lipogenic actions of insulin are controlled by the sterol
response element binding proteins (SREBPs), with SREBP1c be-
ing more selective toward fatty acid and triglyceride synthesis
and SREBP2 stimulation of cholesterol synthesis (Horton
et al., 2002). Although the active SREBP1 isoform is induced
by insulin in both tissues, the transcriptional profile from liver is
most consistent with SREBP2 activation, whereas in muscle,
SREBP1c is likely the dominant isoform. This agrees with previ-
ous observations of impaired SREBP2-mediated cholestero-
genic gene expression in livers lacking IR expression specifically
in hepatocytes (Miao et al., 2014). Motif analysis also indicate
potential SREBP1 target genes involved in functions other than
lipid metabolism, including transcription, chromatin modifica-
tion, and notch and wnt signaling that are suppressed during
the clamp. This is in line with previous reports of downregulation
of genes involved in gluconeogenesis, cytochrome P450, and
IRS-2-mediated signaling by SREBPs (Ide et al., 2004; Jang
et al., 2016; Yamamoto et al., 2004).
Another aspect of metabolic regulation revealed by this study
is the important role of insulin in regulation of ncRNAs. ncRNAs
have gained increased attention in genetic research, because
more than 85% of SNPs associated with T2D occur in non-cod-
ing intronic or intergenic regions of the genome (Jenkinson et al.,
2015). In addition, dysregulated expression of lncRNAs has been
demonstrated under diabetic conditions (He et al., 2017). How-
ever, a comprehensive understanding of lncRNA regulation by
metabolic signals and downstream functions is lacking. We
find that lncRNA regulation accounts for a significant part of
the transcriptional response to insulin in muscle and liver. This
is not limited to the clamp but is also observed by physiological
insulin oscillations induced by fasting and refeeding. One such
example is Gm15441, which is upregulated >100-fold by fasting
and promptly returns to basal levels after refeeding, consistent
with its downregulation during the clamp. This is in line with an
upregulation of this lncRNA in livers of mice on a ketogenic
diet, which lowers insulin levels (Newman et al., 2017).
Correlation between levels of Gm15441 with expression of
FAO genes suggested a role for this lncRNA in regulating lipid
metabolism. Knockdown of Gm15441 lowered palmitic acid-
derived CO2 and ketone body formation. Further studies are
needed to determine precisely how Gm15441 regulates lipid
metabolism, but our study provides two important facets of
this mechanism. First, PPAR nuclear receptors are likely to be
involved, because the expression of Ppar gamma and its co-
activator PGC1a are downregulated by more than 50% upon
knockdown of Gm15441. Although FAO is linked to Ppar alpha,
whose expression was unchanged in our knockdown experi-
ments, previous studies have shown that lower levels of
PGC1 in the liver can also affect FAO (Chambers et al., 2012;
Estall et al., 2009). Second, the lack of regulation of neighboring
genes upon Gm15441 and Gm15663 knockdown and the
different chromosomal location of potential targets PPARg
and PGC1a from these lncRNAs suggest a long-range trans
acting mechanism.
(C and D) qPCR analysis of genes involved in lipid transport and oxidation normalized to 18S (C) and CPT1A and HADHA protein levels normalized to vinculin in
mouse primary hepatocytes 24 h after transfection with siRNAs against ofGm11967,Gm15663, andGm15441 (D). Data are means ± SEM. Hepatocyte cultures
from 4–5 mice were used. *p < 0.05, **p < 0.01, Student’s t test. See also Tables S5 and S6.
(E) Intracellular triglyceride accumulation in AML-12 hepatocytes treated with 500 mM palmitic acid or vehicle for 8 h.
(F and G) 14C palmitic acid oxidation and b-hydroxybutyrate levels in culture supernatants (F) and 14C palmitic acid uptake in AML-12 hepatocytes (G). Lipid
metabolism was assessed 24–36 h after transfection with siRNAs against Gm15441 or scramble controls. Data are means ± SEM, n = 5–6 biological replicates,
*p < 0.05, **p < 0.01, ****p < 0.0001, Student’s t test.
See also Figures S6 and S7.
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In conclusion, insulin promotes rapid and tissue-specific re-
modeling of gene transcription in vivo involving multiple layers
of regulation. These changes extend include aspects not previ-
ously linked to diabetes, such as transcriptional regulation of
lipid metabolism by ncRNAs. This network of gene regulation
provides potential targets for therapeutic approaches involving
insulin action in muscle and liver.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILS
B Animals
B In vitro cell models
d METHOD DETAILS
B Non-labeled Hyperinsulinemic-Euglycemic Clamp
B mRNA isolation, RNA-sequencing and qPCR
B Bioinformatics analysis
B Protein extraction and immunoblotting
B LncRNA knockdown
B Fatty acid accumulation, oxidation and uptake
d QUANTIFICATION AND STATISTICAL ANALYSIS
d DATA AND SOFTWARE AVAILABILITY
SUPPLEMENTAL INFORMATION
Supplemental Information can be found with this article online at https://doi.
org/10.1016/j.celrep.2019.02.081.
ACKNOWLEDGMENTS
This work was supported by NIH grants R37DK031036, R01DK033201 (to
C.R.K.), P30DK036836 (to Joslin Diabetes Center), and 5U2C-DK093000
(to J.K.K.) and the Mary K. Iacocca Professorship (to C.R.K.). T.M.B. was
partially supported by a grant from Sao Paulo Research Foundation (2014/
25370-8). R.G.M. was supported by a Deutsche Forschungsgemeinschaft
(DFG) fellowship (GA 2426/1-1). B.T.O. was funded by a K08 training award
(K08DK100543) and an R03 award (R03DK112003) from the NIDDK of the
NIH. We thank Jonathan M. Dreyfuss and Hui Pan from Joslin Diabetes
Center DRC Genomics and Bioinformatics Core for assistance with data
analysis.
AUTHOR CONTRIBUTIONS
T.M.B. designed research, performed experiments, analyzed the data, and
wrote the paper. W.C., R.G.-M., M.K., B.T.O., and M.S. helped with experi-
ments, review, and editing of the manuscript. D.Y.J. and J.H.K. performed
the hyperinsulinemic-euglycemic clamps. J.K.K. supervised clamp studies.
C.R.K. designed the research, wrote the paper, and supervised the project.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: August 27, 2018
Revised: January 11, 2019
Accepted: February 21, 2019
Published: March 19, 2019
REFERENCES
Abdulla, H., Smith, K., Atherton, P.J., and Idris, I. (2016). Role of insulin in the
regulation of human skeletal muscle protein synthesis and breakdown: a sys-
tematic review and meta-analysis. Diabetologia 59, 44–55.
Akie, T.E., and Cooper, M.P. (2015). Determination of Fatty Acid Oxidation and
Lipogenesis in Mouse Primary Hepatocytes. J. Vis. Exp. 102, e52982.
Almind, K., and Kahn, C.R. (2004). Genetic determinants of energy expenditure
and insulin resistance in diet-induced obesity in mice. Diabetes 53, 3274–
3285.
Andrikopoulos, S., Blair, A.R., Deluca, N., Fam, B.C., and Proietto, J. (2008).
Evaluating the glucose tolerance test in mice. Am. J. Physiol. Endocrinol.
Metab. 295, E1323–E1332.
Ayala, J.E., Bracy, D.P., McGuinness, O.P., and Wasserman, D.H. (2006).
Considerations in the design of hyperinsulinemic-euglycemic clamps in the
conscious mouse. Diabetes 55, 390–397.
Azcoitia, V., Aracil, M., Martı´nez-A, C., and Torres, M. (2005). The homeodo-
main protein Meis1 is essential for definitive hematopoiesis and vascular
patterning in the mouse embryo. Dev. Biol. 280, 307–320.
Berglund, E.D., Li, C.Y., Poffenberger, G., Ayala, J.E., Fueger, P.T., Willis, S.E.,
Jewell, M.M., Powers, A.C., and Wasserman, D.H. (2008). Glucose meta-
bolism in vivo in four commonly used inbred mouse strains. Diabetes 57,
1790–1799.
Borghini, S., Bachetti, T., Fava, M., Di Duca, M., Cargnin, F., Fornasari, D.,
Ravazzolo, R., and Ceccherini, I. (2006). The TLX2 homeobox gene is a tran-
scriptional target of PHOX2B in neural-crest-derived cells. Biochem. J. 395,
355–361.
Boucher, J., Tseng, Y.H., and Kahn, C.R. (2010). Insulin and insulin-like growth
factor-1 receptors act as ligand-specific amplitude modulators of a common
pathway regulating gene transcription. J. Biol. Chem. 285, 17235–17245.
Boucher, J., Kleinridders, A., and Kahn, C.R. (2014). Insulin receptor signaling
in normal and insulin-resistant states. Cold Spring Harb. Perspect. Biol. 6,
a009191.
Chambers, K.T., Chen, Z., Crawford, P.A., Fu, X., Burgess, S.C., Lai, L., Leone,
T.C., Kelly, D.P., and Finck, B.N. (2012). Liver-specific PGC-1beta deficiency
leads to impaired mitochondrial function and lipogenic response to fasting-re-
feeding. PLoS ONE 7, e52645.
Chen, M., and Manley, J.L. (2009). Mechanisms of alternative splicing regula-
tion: insights from molecular and genomics approaches. Nat. Rev. Mol. Cell
Biol. 10, 741–754.
Cho, Y., Hazen, B.C., Russell, A.P., and Kralli, A. (2013). Peroxisome prolifer-
ator-activated receptor g coactivator 1 (PGC-1)- and estrogen-related recep-
tor (ERR)-induced regulator inmuscle 1 (Perm1) is a tissue-specific regulator of
oxidative capacity in skeletal muscle cells. J. Biol. Chem. 288, 25207–25218.
Chutkow, W.A., Birkenfeld, A.L., Brown, J.D., Lee, H.Y., Frederick, D.W.,
Yoshioka, J., Patwari, P., Kursawe, R., Cushman, S.W., Plutzky, J., et al.
(2010). Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity
and adipogenesis while preserving insulin sensitivity. Diabetes 59, 1424–1434.
Coletta, D.K., Balas, B., Chavez, A.O., Baig, M., Abdul-Ghani, M., Kashyap,
S.R., Folli, F., Tripathy, D., Mandarino, L.J., Cornell, J.E., et al. (2008). Effect
of acute physiological hyperinsulinemia on gene expression in human skeletal
muscle in vivo. Am. J. Physiol. Endocrinol. Metab. 294, E910–E917.
Cunningham, J.T., Rodgers, J.T., Arlow, D.H., Vazquez, F., Mootha, V.K., and
Puigserver, P. (2007). mTOR controls mitochondrial oxidative function through
a YY1-PGC-1alpha transcriptional complex. Nature 450, 736–740.
Davis, C.A., Hitz, B.C., Sloan, C.A., Chan, E.T., Davidson, J.M., Gabdank, I.,
Hilton, J.A., Jain, K., Baymuradov, U.K., Narayanan, A.K., et al. (2018). The
Encyclopedia of DNA elements (ENCODE): data portal update. Nucleic Acids
Res. 46 (D1), D794–D801.
Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A.,
Blandino, G., and Piaggio, G. (2006). Gain of function of mutant p53: the
mutant p53/NF-Y protein complex reveals an aberrant transcriptional mecha-
nism of cell cycle regulation. Cancer Cell 10, 191–202.
Cell Reports 26, 3429–3443, March 19, 2019 3441
Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut,
P., Chaisson,M., andGingeras, T.R. (2013). STAR: ultrafast universal RNA-seq
aligner. Bioinformatics 29, 15–21.
Estall, J.L., Kahn, M., Cooper, M.P., Fisher, F.M., Wu, M.K., Laznik, D., Qu, L.,
Cohen, D.E., Shulman, G.I., and Spiegelman, B.M. (2009). Sensitivity of lipid
metabolism and insulin signaling to genetic alterations in hepatic peroxisome
proliferator-activated receptor-gamma coactivator-1alpha expression. Dia-
betes 58, 1499–1508.
Farmer, T.D., Jenkins, E.C., O’Brien, T.P., McCoy, G.A., Havlik, A.E., Nass,
E.R., Nicholson, W.E., Printz, R.L., and Shiota, M. (2015). Comparison of the
physiological relevance of systemic vs. portal insulin delivery to evaluate whole
body glucose flux during an insulin clamp. Am. J. Physiol. Endocrinol. Metab.
308, E206–E222.
Fazakerley, D.J., Chaudhuri, R., Yang, P., Maghzal, G.J., Thomas, K.C.,
Krycer, J.R., Humphrey, S.J., Parker, B.L., Fisher-Wellman, K.H., Meoli,
C.C., et al. (2018). Mitochondrial CoQ deficiency is a common driver of mito-
chondrial oxidants and insulin resistance. eLife 7, e32111.
Franko, A., von Kleist-Retzow, J.C., Neschen, S., Wu, M., Schommers, P.,
Bo¨se, M., Kunze, A., Hartmann, U., Sanchez-Lasheras, C., Stoehr, O., et al.
(2014). Liver adapts mitochondrial function to insulin resistant and diabetic
states in mice. J. Hepatol. 60, 816–823.
Granner, D.K. (2015). In pursuit of genes of glucosemetabolism. J. Biol. Chem.
290, 22312–22324.
Haeusler, R.A., Hartil, K., Vaitheesvaran, B., Arrieta-Cruz, I., Knight, C.M.,
Cook, J.R., Kammoun, H.L., Febbraio, M.A., Gutierrez-Juarez, R., Kurland,
I.J., and Accili, D. (2014). Integrated control of hepatic lipogenesis versus
glucose production requires FoxO transcription factors. Nat. Commun. 5,
5190.
Haeusler, R.A., McGraw, T.E., and Accili, D. (2018). Biochemical and cellular
properties of insulin receptor signalling. Nat. Rev. Mol. Cell Biol. 19, 31–44.
He, X., Ou, C., Xiao, Y., Han, Q., Li, H., and Zhou, S. (2017). LncRNAs: key
players and novel insights into diabetes mellitus. Oncotarget 8, 71325–71341.
Hirota, K., Sakamaki, J., Ishida, J., Shimamoto, Y., Nishihara, S., Kodama, N.,
Ohta, K., Yamamoto, M., Tanimoto, K., and Fukamizu, A. (2008). A combina-
tion of HNF-4 and Foxo1 is required for reciprocal transcriptional regulation
of glucokinase and glucose-6-phosphatase genes in response to fasting and
feeding. J. Biol. Chem. 283, 32432–32441.
Horton, J.D., Goldstein, J.L., and Brown, M.S. (2002). SREBPs: activators of
the complete program of cholesterol and fatty acid synthesis in the liver.
J. Clin. Invest. 109, 1125–1131.
Hota, S.K., and Bruneau, B.G. (2016). ATP-dependent chromatin remodeling
during mammalian development. Development 143, 2882–2897.
Huang, W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integra-
tive analysis of large gene lists using DAVID bioinformatics resources. Nat.
Protoc. 4, 44–57.
Ide, T., Shimano, H., Yahagi, N., Matsuzaka, T., Nakakuki, M., Yamamoto, T.,
Nakagawa, Y., Takahashi, A., Suzuki, H., Sone, H., et al. (2004). SREBPs sup-
press IRS-2-mediated insulin signalling in the liver. Nat. Cell Biol. 6, 351–357.
Jang, H., Lee, G.Y., Selby, C.P., Lee, G., Jeon, Y.G., Lee, J.H., Cheng, K.K.,
Titchenell, P., Birnbaum, M.J., Xu, A., et al. (2016). SREBP1c-CRY1 signalling
represses hepatic glucose production by promoting FOXO1 degradation dur-
ing refeeding. Nat. Commun. 7, 12180.
Jenkinson, C.P., Go¨ring, H.H., Arya, R., Blangero, J., Duggirala, R., and
DeFronzo, R.A. (2015). Transcriptomics in type 2 diabetes: Bridging the gap
between genotype and phenotype. Genom. Data 8, 25–36.
Karakelides, H., Asmann, Y.W., Bigelow, M.L., Short, K.R., Dhatariya, K.,
Coenen-Schimke, J., Kahl, J., Mukhopadhyay, D., and Nair, K.S. (2007). Effect
of insulin deprivation on muscle mitochondrial ATP production and gene tran-
script levels in type 1 diabetic subjects. Diabetes 56, 2683–2689.
Kim, J.K. (2009). Hyperinsulinemic-euglycemic clamp to assess insulin sensi-
tivity in vivo. Methods Mol. Biol. 560, 221–238.
Kivela¨, R., Silvennoinen, M., Touvra, A.M., Lehti, T.M., Kainulainen, H., and
Vihko, V. (2006). Effects of experimental type 1 diabetes and exercise training
on angiogenic gene expression and capillarization in skeletal muscle. FASEB
J. 20, 1570–1572.
Lan, H., Rabaglia, M.E., Stoehr, J.P., Nadler, S.T., Schueler, K.L., Zou, F., Yan-
dell, B.S., and Attie, A.D. (2003). Gene expression profiles of nondiabetic and
diabetic obese mice suggest a role of hepatic lipogenic capacity in diabetes
susceptibility. Diabetes 52, 688–700.
Law, C.W., Chen, Y., Shi, W., and Smyth, G.K. (2014). voom: Precision weights
unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15,
R29.
Li, P., Ruan, X., Yang, L., Kiesewetter, K., Zhao, Y., Luo, H., Chen, Y., Gucek,
M., Zhu, J., and Cao, H. (2015). A liver-enriched long non-coding RNA,
lncLSTR, regulates systemic lipid metabolism in mice. Cell Metab. 21,
455–467.
Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general
purpose program for assigning sequence reads to genomic features. Bioinfor-
matics 30, 923–930.
Lu, M., Wan, M., Leavens, K.F., Chu, Q., Monks, B.R., Fernandez, S., Ahima,
R.S., Ueki, K., Kahn, C.R., and Birnbaum, M.J. (2012). Insulin regulates liver
metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat. Med. 18,
388–395.
Matsumoto, M., Pocai, A., Rossetti, L., Depinho, R.A., and Accili, D. (2007).
Impaired regulation of hepatic glucose production in mice lacking the forkhead
transcription factor Foxo1 in liver. Cell Metab. 6, 208–216.
Matveyenko, A.V., Liuwantara, D., Gurlo, T., Kirakossian, D., Dalla Man, C.,
Cobelli, C., White, M.F., Copps, K.D., Volpi, E., Fujita, S., and Butler, P.C.
(2012). Pulsatile portal vein insulin delivery enhances hepatic insulin action
and signaling. Diabetes 61, 2269–2279.
Miao, J., Haas, J.T., Manthena, P., Wang, Y., Zhao, E., Vaitheesvaran, B., Kur-
land, I.J., and Biddinger, S.B. (2014). Hepatic insulin receptor deficiency im-
pairs the SREBP-2 response to feeding and statins. J. Lipid Res. 55, 659–667.
Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Le-
har, J., Puigserver, P., Carlsson, E., Ridderstra˚le, M., Laurila, E., et al. (2003).
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coor-
dinately downregulated in human diabetes. Nat. Genet. 34, 267–273.
Mootha, V.K., Handschin, C., Arlow, D., Xie, X., St Pierre, J., Sihag, S., Yang,
W., Altshuler, D., Puigserver, P., Patterson, N., et al. (2004). Erralpha and
Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene
expression that is altered in diabetic muscle. Proc. Natl. Acad. Sci. USA
101, 6570–6575.
Mounier, C., and Posner, B.I. (2006). Transcriptional regulation by insulin: from
the receptor to the gene. Can. J. Physiol. Pharmacol. 84, 713–724.
Nakae, J., Barr, V., and Accili, D. (2000). Differential regulation of gene expres-
sion by insulin and IGF-1 receptors correlates with phosphorylation of a single
amino acid residue in the forkhead transcription factor FKHR. EMBO J. 19,
989–996.
Nepusz, T., Yu, H., and Paccanaro, A. (2012). Detecting overlapping protein
complexes in protein-protein interaction networks. Nat. Methods 9, 471–472.
Newman, J.C., Covarrubias, A.J., Zhao, M., Yu, X., Gut, P., Ng, C.P., Huang,
Y., Haldar, S., and Verdin, E. (2017). Ketogenic Diet Reduces Midlife Mortality
and Improves Memory in Aging Mice. Cell Metab. 26, 547–557.
O-Sullivan, I., Zhang, W., Wasserman, D.H., Liew, C.W., Liu, J., Paik, J.,
DePinho, R.A., Stolz, D.B., Kahn, C.R., Schwartz, M.W., and Unterman, T.G.
(2015). FoxO1 integrates direct and indirect effects of insulin on hepatic
glucose production and glucose utilization. Nat. Commun. 6, 7079.
O’Neill, B.T., Lauritzen, H.P., Hirshman, M.F., Smyth, G., Goodyear, L.J., and
Kahn, C.R. (2015). Differential Role of Insulin/IGF-1 Receptor Signaling in
Muscle Growth and Glucose Homeostasis. Cell Rep. 11, 1220–1235.
O’Neill, B.T., Lee, K.Y., Klaus, K., Softic, S., Krumpoch, M.T., Fentz, J., Stan-
ford, K.I., Robinson, M.M., Cai, W., Kleinridders, A., et al. (2016). Insulin and
IGF-1 receptors regulate FoxO-mediated signaling in muscle proteostasis.
J. Clin. Invest. 126, 3433–3446.
O’Neill, B.T., Bhardwaj, G., Penniman, C.M., Krumpoch, M.T., Suarez Beltran,
P.A., Klaus, K., Poro, K., Li, M., Pan, H., Dreyfuss, J.M., et al. (2019). FoxO
3442 Cell Reports 26, 3429–3443, March 19, 2019
Transcription Factors are Critical Regulators of Diabetes-RelatedMuscle Atro-
phy. Diabetes 68, 556–570.
Parikh, H., Carlsson, E., Chutkow, W.A., Johansson, L.E., Storgaard, H., Poul-
sen, P., Saxena, R., Ladd, C., Schulze, P.C., Mazzini, M.J., et al. (2007). TXNIP
regulates peripheral glucose metabolism in humans. PLoS Med. 4, e158.
Patti, M.E. (2004). Gene expression in the pathophysiology of type 2 diabetes
mellitus. Curr. Diab. Rep. 4, 176–181.
Patti, M.E., Butte, A.J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S., Miya-
zaki, Y., Kohane, I., Costello, M., Saccone, R., et al. (2003). Coordinated reduc-
tion of genes of oxidative metabolism in humans with insulin resistance and
diabetes: Potential role of PGC1 and NRF1. Proc. Natl. Acad. Sci. USA 100,
8466–8471.
Postic, C., Shiota, M., Niswender, K.D., Jetton, T.L., Chen, Y., Moates, J.M.,
Shelton, K.D., Lindner, J., Cherrington, A.D., and Magnuson, M.A. (1999).
Dual roles for glucokinase in glucose homeostasis as determined by liver
and pancreatic beta cell-specific gene knock-outs using Cre recombinase.
J. Biol. Chem. 274, 305–315.
Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K.
(2015). limma powers differential expression analyses for RNA-sequencing
and microarray studies. Nucleic Acids Res. 43, e47.
Rome, S., Cle´ment, K., Rabasa-Lhoret, R., Loizon, E., Poitou, C., Barsh, G.S.,
Riou, J.P., Laville, M., and Vidal, H. (2003). Microarray profiling of human skel-
etal muscle reveals that insulin regulates approximately 800 genes during a
hyperinsulinemic clamp. J. Biol. Chem. 278, 18063–18068.
Salatino, S., Kupr, B., Baresic, M., Omidi, S., van Nimwegen, E., and Hand-
schin, C. (2016). The Genomic Context and Corecruitment of SP1 Affect
ERRa Coactivation by PGC-1a in Muscle Cells. Mol. Endocrinol. 30, 809–825.
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K.,
Schiaffino, S., Lecker, S.H., and Goldberg, A.L. (2004). Foxo transcription
factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal
muscle atrophy. Cell 117, 399–412.
Sears, D.D., Hsiao, G., Hsiao, A., Yu, J.G., Courtney, C.H., Ofrecio, J.M.,
Chapman, J., and Subramaniam, S. (2009). Mechanisms of human insulin
resistance and thiazolidinedione-mediated insulin sensitization. Proc. Natl.
Acad. Sci. USA 106, 18745–18750.
Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin,
N., Schwikowski, B., and Ideker, T. (2003). Cytoscape: a software environment
for integrated models of biomolecular interaction networks. Genome Res. 13,
2498–2504.
Sheaffer, K.L., and Kaestner, K.H. (2012). Transcriptional networks in liver and
intestinal development. Cold Spring Harb. Perspect. Biol. 4, a008284.
Shen, H.Q., Zhu, J.S., and Baron, A.D. (1999). Dose-response relationship of
insulin to glucose fluxes in the awake and unrestrained mouse. Metabolism
48, 965–970.
Steele, A.M., Shields, B.M., Wensley, K.J., Colclough, K., Ellard, S., and Hat-
tersley, A.T. (2014). Prevalence of vascular complications among patients with
glucokinase mutations and prolonged, mild hyperglycemia. JAMA 311,
279–286.
Szklarczyk, D., Morris, J.H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M.,
Santos, A., Doncheva, N.T., Roth, A., Bork, P., et al. (2017). The STRING data-
base in 2017: quality-controlled protein-protein association networks, made
broadly accessible. Nucleic Acids Res. 45 (D1), D362–D368.
Taniguchi, C.M., Emanuelli, B., and Kahn, C.R. (2006). Critical nodes in signal-
ling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 85–96.
Thiebaud, D., Jacot, E., DeFronzo, R.A., Maeder, E., Jequier, E., and Felber,
J.P. (1982). The effect of graded doses of insulin on total glucose uptake,
glucose oxidation, and glucose storage in man. Diabetes 31, 957–963.
Tokarz, V.L., MacDonald, P.E., and Klip, A. (2018). The cell biology of systemic
insulin function. J. Cell Biol. 217, 2273–2289.
Tu, Z., Prajapati, S., Park, K.J., Kelly, N.J., Yamamoto, Y., and Gaynor, R.B.
(2006). IKK alpha regulates estrogen-induced cell cycle progression by modu-
lating E2F1 expression. J. Biol. Chem. 281, 6699–6706.
Villegas, V.E., and Zaphiropoulos, P.G. (2015). Neighboring gene regulation by
antisense long non-coding RNAs. Int. J. Mol. Sci. 16, 3251–3266.
Wang, Y.M., Ong, S.S., Chai, S.C., and Chen, T. (2012). Role of CAR and PXR
in xenobiotic sensing and metabolism. Expert Opin. Drug Metab. Toxicol. 8,
803–817.
Wolfrum, C., Besser, D., Luca, E., and Stoffel, M. (2003). Insulin regulates the
activity of forkhead transcription factor Hnf-3beta/Foxa-2 by Akt-mediated
phosphorylation and nuclear/cytosolic localization. Proc. Natl. Acad. Sci.
USA 100, 11624–11629.
Wu, D., Lim, E., Vaillant, F., Asselin-Labat, M.L., Visvader, J.E., and Smyth,
G.K. (2010). ROAST: rotation gene set tests for complex microarray experi-
ments. Bioinformatics 26, 2176–2182.
Xu, H., He, J.H., Xiao, Z.D., Zhang, Q.Q., Chen, Y.Q., Zhou, H., and Qu, L.H.
(2010). Liver-enriched transcription factors regulate microRNA-122 that tar-
gets CUTL1 during liver development. Hepatology 52, 1431–1442.
Yamamoto, T., Shimano, H., Nakagawa, Y., Ide, T., Yahagi, N., Matsuzaka, T.,
Nakakuki, M., Takahashi, A., Suzuki, H., Sone, H., et al. (2004). SREBP-1 inter-
acts with hepatocyte nuclear factor-4 alpha and interferes with PGC-1 recruit-
ment to suppress hepatic gluconeogenic genes. J. Biol. Chem. 279, 12027–
12035.
Yang, L., Li, P., Yang,W., Ruan, X., Kiesewetter, K., Zhu, J., andCao, H. (2016).
Integrative Transcriptome Analyses of Metabolic Responses in Mice Define
Pivotal LncRNA Metabolic Regulators. Cell Metab. 24, 627–639.
Yechoor, V.K., Patti, M.E., Ueki, K., Laustsen, P.G., Saccone, R., Rauniyar, R.,
and Kahn, C.R. (2004). Distinct pathways of insulin-regulated versus diabetes-
regulated gene expression: an in vivo analysis in MIRKO mice. Proc. Natl.
Acad. Sci. USA 101, 16525–16530.
Yip, L., and Fathman, C.G. (2014). Type 1 diabetes in mice and men: gene
expression profiling to investigate disease pathogenesis. Immunol. Res. 58,
340–350.
Cell Reports 26, 3429–3443, March 19, 2019 3443
STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Phospho-IGF-I Receptor b (Tyr1135/1136)/Insulin Receptor b
(Tyr1150/1151) (19H7)
Cell Signaling Technology Cat# 3024; RRID:AB_331253
IGF-I Receptor b Cell Signaling Technology Cat# 3027; RRID:AB_2122378
Phospho-AKT (Ser473) Cell Signaling Technology Cat# 9271; RRID:AB_329825
Akt (pan) (11E7) Cell Signaling Technology Cat# 4685; RRID:AB_2225340
Phospho-FOXO1 (Thr24)/FOXO3A (Thr32) Cell Signaling Technology Cat# 9464; RRID:AB_329842
FOXO1 Cell Signaling Technology Cat# 9454; RRID:AB_823503
p44/42 MAP kinase (phosphorylated Erk1/2) Cell Signaling Technology Cat# 9101; RRID:AB_331646
p44/42 MAPK (Erk1/2) Cell Signaling Technology Cat# 9102; RRID:AB_330744
Insulin Receptor beta (C-19) Santa Cruz Biotechnology Cat# sc-711; RRID:AB_631835
Phospho-IRS1 (Tyr608) mouse/ (Tyr612) human Millipore Cat# 09-432; RRID:AB_1163457
IRS-1 BD Biosciences Cat# 611394; RRID:AB_398916
Vinculin, clone VIIF9 (7F9) Millipore Cat# MAB3574; RRID:AB_2304338
CPT1A [8F6AE9] Abcam Cat# ab128568; RRID:AB_11141632
HADHA Abcam Cat# ab54477; RRID:AB_2263836
SREBP1 Santa Cruz Biotechnology Cat# sc-8984; RRID:AB_2194223
Fatty Acid Synthase Abcam Cat# ab22759; RRID:AB_732316
Chemicals, Peptides, and Recombinant Proteins
RIPA Lysis Buffer, 10X for Immunoprecipitation & Western Blotting Millipore Cat# 20-188
Collagenase, Type I from Clostridium histolyticum GIBCO Cat# 17100017
Collagen from calf skin Sigma-Aldrich Cat# C8919; CAS: 9007-34-5
Lipofectamine RNAiMAX Transfection Reagent Invitrogen Cat# 13778030
PALMITIC ACID, [1-14C]-, 50 mCi Perkin Elmer Cat# NEC075H050UC
Critical Commercial Assays
b-Hydroxybutyrate (Ketone Body) Fluorometric Assay Kit Cayman Chemical Cat# 700740
Triglyceride Enzymatic Assay Pointe Scientific Cat# T7532
Deposited Data
Raw sequence data (muscle and liver) This paper GEO: GSE117741
Expression profiling by array Almind and Kahn, 2004 GEO: GSE123394
Experimental Models: Cell Lines
Mouse: AML12 hepatocytes ATCC Cat# CRL-2254; RRID:CVCL_0140
Experimental Models: Organisms/Strains
Mouse: C57BL/6J The Jackson Laboratory Cat# 000664
Oligonucleotides
siRNA against Gm11967 (sense): 50 CAGAAGAUGAUGAUCGGAUUU 30 This paper N/A
siRNA against Gm11967 (antisense): 50 AUCCGAUCAUCAUCUUCUGUU 30 This paper N/A
siRNA against Gm15663 (sense): 50 GAAAUACGGUGCAGAAGAAUU 30, This paper N/A
siRNA against Gm15663 (antisense): 50 UUCUUCUGCACCGUAUUUCUU 30 This paper N/A
siRNA against Gm15441 (sense): 50 ACAUAAGACUUCAGGAGAAUU 30, This paper N/A
siRNA against Gm15441 (antisense): 50 UUCUCCUGAAGUCUUAUGUUU 30 This paper N/A
Software and Algorithms
STAR Dobin et al., 2013 http://code.google.com/p/rna-star/
The R Project for Statistical Computing Freely available online https://www.r-project.org/
(Continued on next page)
e1 Cell Reports 26, 3429–3443.e1–e3, March 19, 2019
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents and resources should be directed to andwill be fulfilled by the Lead Contact, C. Ronald
Kahn (c.ronald.kahn@joslin.harvard.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
Experiments were performed on three month-old male C57BL/6J mice (Jackson Laboratories). Mice were housed in standard
conditions under 12-hour light/12-hour dark cycle and fed a 22% fat chow diet (Mouse Diet 9F, LabDiet). All procedures described
were approved by the IACUC of the Joslin Diabetes Center, Boston, MA 02215 and University of Massachusetts Medical School,
Worcester, MA 01655, and were in accordance with NIH guidelines.
In vitro cell models
For primary hepatocyte isolation, mouse livers were perfused through the inferior cava vein with PBS-EDTA, followed by perfusion
with a pre-warmed type I collagenase solution (GIBCO, catalog 17100017). Hepatocytes were released from excised livers in a 10 cm
Petri dish, following two cycles of filtering through a 100 mm strainer and centrifugation at 50 g for 90 s at 4C. Hepatocytes from
preparations with 85% viability or higher, determined by trypan blue staining, were plated in 6-well plates pre-coated with collagen
I (Sigma, catalog C8919). Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal bovine serum
(FBS) and 100 units of penicillin-streptomycin.
Mouse TGFa-immortalized AML-12 hepatocytes were maintained in DMEM/F12 medium containing 10% FBS, 10 mg/mL insulin,
5.5 mg/mL transferrin, 5 ng/mL selenium, 40 ng/mL dexamethasone, 11 mg/mL sodium pyruvate and 100 units of penicillin-strepto-
mycin. All cells were maintained in a humidified incubator at 37C and 5% CO2.
METHOD DETAILS
Non-labeled Hyperinsulinemic-Euglycemic Clamp
Mice (n = 6 per condition) were anestethized with a mixture of ketamine/xylazine and had an indwelling catheter placed in the right
internal jugular vein. After recovery (4-5 days)micewere fasted overnight (16 hr) and placed on rat-sized restrainers. After acclimation
period, mice received an insulin bolus of 16 or 48mU/kg andwere continuously perfusedwith either 4 or 12mU/kg/min insulin or saline
ascontrol. Bloodsampleswerecollected from the tail tip at 5min intervals (for the20minclamp)or 10-30min intervals (for the3hclamp),
and a 20%glucose solution was infused to maintain blood glucose levels at euglycemia (110 to 150mg/dL). At 20 min or 3 h of clamp,
micewereeuthanizedbycervicaldislocation, and tissueswereharvested, snap frozen in liquidnitrogenandkept at80Cuntil analysis.
These in vivo experiments were conducted at the National Mouse Metabolic Phenotyping Center (MMPC) at UMass Medical School.
mRNA isolation, RNA-sequencing and qPCR
Total RNA was isolated from quadriceps muscle and liver fragments homogenized in QIAzol reagent (QIAGEN), followed by
chlorophorm/isopropanol/ethanol extraction. RNA quality and quantification was verified at the Joslin Genomics Core using a
2100 Agilent Bioanalyzer instrument. Total RNA samples (2 mg) that passed quality test (RNA integrity score > 7), were submitted
to the Biopolymers Facility at Harvard Medical School. Stranded cDNA libraries with unique index tags for each sample (48 multi-
plexed) were made using a directional RNA-seq kit (Wafergen). Sequencing was performed on a Illumina HiSeq 2500 run on rapid
mode (2x50). qPCR reactions were prepared using iQ SybrGreen Supermix (Bio-Rad, catalog 1708884) and run on a C1000 Thermal
Cycler (BioRad, catalogCFX384) using TATA box binding protein (Tbp) or 18S ribosomal RNA as internal controls as indicated. Primer
sequences used are listed in Table S7.
Bioinformatics analysis
Reads were aligned to the mouse genome from Gencode (GRCm38.p4) using STAR (Dobin et al., 2013) and counted with feature-
Counts (Liao et al., 2014). Read counts were transformed to log2-counts per million (LogCPM), their mean-variance relationship was
Continued
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STRING Szklarczyk et al., 2017 https://string-db.org/
Cytoscape Shannon et al., 2003 https://cytoscape.org
ClusterOne Nepusz et al., 2012 http://www.paccanarolab.org/
cluster-one/
DAVID Huang et al., 2009 https://david.ncifcrf.gov/
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estimated, their weights were computed with voom (Law et al., 2014), and their differential expression was assessed using linear
modeling with the R package limma (Ritchie et al., 2015). P values were corrected using the Benjamini-Hochberg false discovery
rate (FDR), and FDR < 0.1 was considered statistically significant. Gene sets based on transcription factor targets, Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) and Gene Ontology Biological Process (BP) databases were tested using the limma Roast
method (Wu et al., 2010).
Gene expression networks were designed by uploading differentially expressed genes to STRING database (Szklarczyk et al.,
2017) and were further modeled in Cytoscape (Shannon et al., 2003). Gene clusters were identified using KEGG gene sets and
ClusterOne function (Nepusz et al., 2012). Functional annotation analysis was perfomed using the DAVID platform V6.8 (Huang
et al., 2009).
Protein extraction and immunoblotting
Tissue fragments and cells were homogenized in RIPA buffer (EMD Millipore) supplemented with protease and phosphatase inhib-
itors (Biotool). Lysates were separated from insoluble material by centrifugation (12,000 RPM, 15 min, 4C) and total protein content
was determined by BCA assay (ThermoFisher). Equal protein ammounts (10 mg) were resolved by SDS-PAGE and transferred to
polyvinylidene fluoride (PVDF) membranes (EMD Millipore). Membranes were immunoblotted with the indicated antibodies: p-IR/
IGF1R (#3024, Cell Signaling), IRb (sc-711, Santa Cruz), IGF1Rb (#3027, Cell Signaling), p-IRS1 (09-432, Millipore), IRS1 (611394,
BD), p-AktS473 (#9271, Cel Signaling), Akt pan (#4685, Cell Signaling), p-FOXO1/3 (#9464, Cell Signaling), FoxO1 (#9454, Cell
Signaling), p-ERK1/2 (#9101, Cell Signaling), ERK1/2 (#9102, Cell Signaling), CPT1A (ab128568, Abcam), HADHA (ab54477, Abcam),
SREBP1 (sc-8984, Santa Cruz), Fatty Acid Synthase (ab22759, Abcam), Vinculin (#3574, Chemicon).
LncRNA knockdown
Twenty four hours after isolation, primary hepatocytes were transfected with 75 pmoles of custom-made siRNAs (Dharmacon/GE
Lifesciences) against Gm11967, Gm15663, Gm15441 or non-targeting controls using Lipofectamine RNAiMAX (Invitrogen). Twenty
four hours post transfection, cells were washedwith PBS and collected with 1mL TRIzol reagent (Invitrogen) followed by RNA extrac-
tion according to manufacturer’s instructions. Protein extracts were prepared as described above. Mouse AML-12 hepatocytes
were transfected with either 60 pmoles (12-well) or 30 pmoles (24-well) at 70%–80% confluency. All assays were performed within
24-36 h post-transfection. siRNA sequences are as follows: Gm11967 sense 50 CAGAAGAUGAUGAUCGGAUUU 30, antisense
50 AUCCGAUCAUCAUCUUCUGUU 30;Gm15663 sense: 50 GAAAUACGGUGCAGAAGAAUU 30, antisense: 50 UUCUUCUGCACCGU
AUUUCUU 30, Gm15441 sense: 50 ACAUAAGACUUCAGGAGAAUU 30, antisense: 50 UUCUCCUGAAGUCUUAUGUUU 30.
Fatty acid accumulation, oxidation and uptake
For lipid accumulation, cells were pre-incubated overnight (16 h) in DMEM/F12 + 2.5% FBS (no supplements) followed by incuba-
tion with 500 mM palmitic acid (Sigma, catalog P5585) pre-complexed with fatty acid-free bovine serum albumin (FAF-BSA) or BSA-
only as controls for 8 h. Total intracellular triglycerides were measured by an enzymatic plate-based assay (Pointe Scientific) and
normalized to protein content. For FAO, cells were serum-starved in the presence of 0.1% FAF-BSA for 3 h, followed by 1 h with fatty
acid incubationmedia (FAIM) containing 20 mMpalmitic acid conjugatedwith FAF-BSA plus 1 h in the presence of 0.1 mCi 14C palmitic
acid (Perkin Elmer). FAO was determined as the fraction of 14C palmitic acid-derived CO2 trapped in filter papers normalized to pro-
tein content as previously described (Akie and Cooper, 2015). Before addition of 14C palmitic acid, an aliquot of FAIM was collected
and assayed for b-hydroxybutyrate levels using a fluorimetric method (Cayman Chemical) according to manufacturer’s instructions.
For fatty acid uptake, cells were serum-starved for 3 h and incubated with FAIM containing 200 mM palmitic acid conjugated with
FAF-BSA for 30 min plus another 30 min in the presence of 0.1 mCi 14C palmitic acid. Fatty acid uptake was interpreted as pro-
tein-normalized counts from cell lysates.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are presented as means ± SEM. Comparisons between two groups was performed using Student’s t test. Comparisons be-
tween more than two groups was performed using One-way ANOVA followed by post hoc t tests. Comparisons between two groups
and two nominal variables (e.g., basal versus clamp) was performed using Two-way ANOVA followed by Holm-Sidak’s post hoc test.
Statistical analysis was performed using GraphPad Prism (Version 7.02). Significance level was set at p < 0.05.
DATA AND SOFTWARE AVAILABILITY
RNA-seq data described here is deposited in Gene Expression Omnibus (GEO) under accession number GEO: GSE117741. Expres-
sion data from muscle and liver microarrays of HFD C57BL/6 mice are under accession number GEO: GSE123394. The metabolic
phenotype of these mice has been described (Almind and Kahn, 2004). Data-sets from STZ-treatment in mouse muscle GEO:
GSE1659 (Kivela¨ et al., 2006) and liver GEO: GSE39752 (Franko et al., 2014) were downloaded from GEO.
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